Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.65 |
| ▸ | MAPT | P10636 | 4/20 | 0.65 |
| ▸ | LMNA | P02545 | 3/20 | 0.65 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.65 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.65 |
| ▸ | MC4R | P32245 | 1/20 | 0.65 |
| ▸ | SCN4A | P35499 | 1/20 | 0.65 |
| ▸ | MC3R | P41968 | 1/20 | 0.65 |
| ▸ | HTR3A | P46098 | 1/20 | 0.65 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.65 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.65 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.65 |
| ▸ | GAA | P10253 | 5/20 | 0.63 |
| ▸ | BLM | P54132 | 1/20 | 0.63 |
| ▸ | MEN1 | O00255 | 4/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.59 |
| ▸ | HTT | P42858 | 2/20 | 0.55 |
| ▸ | HPGD | P15428 | 2/20 | 0.51 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21264286 | 0.84 | ALDH1A1 (0.64) | ALDH1A1MAPTLMNAMAPK1CYP3A4 | |
| SCHEMBL19002367 | 0.83 | ALDH1A1 (0.76) | ALDH1A1MAPTLMNAMAPK1GAA | |
| SCHEMBL2098520 | 0.82 | ALDH1A1 (0.61) | ALDH1A1MAPTLMNAMAPK1CYP3A4 | |
| SCHEMBL17886503 | 0.80 | MEN1 (0.46) | ALDH1A1MEN1KMT2ATSHR | |
| Lidocaine SCHEMBL3952474 | 0.79 | MAPT (0.94) | ALDH1A1MAPTLMNAMAPK1CYP3A4 | |
| Lidocaine SCHEMBL28197817 | 0.79 | ALDH1A1 (0.85) | ALDH1A1MAPTLMNAMAPK1CYP3A4 | |
| Lidocaine SCHEMBL5334354 | 0.79 | MAPT (1.00) | ALDH1A1MAPTLMNAMAPK1CYP3A4 | |
| SCHEMBL11130240 | 0.79 | TSHR (0.77) | ALDH1A1MAPTLMNAMAPK1CYP3A4 | |
| Lidocaine SCHEMBL8183082 | 0.79 | MAPT (1.00) | ALDH1A1MAPTLMNAMAPK1CYP3A4 | |
| Lidocaine SCHEMBL15689 | 0.79 | MAPT (1.00) | ALDH1A1MAPTLMNAMAPK1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080221206-A1 | Compounds Derived From Lidocaine, Pharmaceutical Compositions, Use And Method Of Treatment, Prevention Or Inhibition Of Disease | FUNDÇÃO OSWALDO CRUZ-FIOCRUZ (BR) | 2008-09-11 | — | — | US | claimed |
| US-8163803-B2 | less anesthetic activity, but with more anti-inflammatory and spasmolytic activity; asthma, rhinitis, allergic urticaria, chronic lung inflammation associated with eosinophilia, following the example of atopic asthma and chronic intestinal inflammation, as colitis for instance | Fundação Oswaldo Cruz—FIOCRUZ (BR) | 2012-04-24 | — | — | US | disclosed |
| US-20080221206-A1 | Compounds Derived From Lidocaine, Pharmaceutical Compositions, Use And Method Of Treatment, Prevention Or Inhibition Of Disease | FUNDÇÃO OSWALDO CRUZ-FIOCRUZ (BR) | 2008-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221206-A1 | Compounds Derived From Lidocaine, Pharmaceutical Compositions, Use And Method Of Treatment, Prevention Or Inhibition Of Disease | LTA, LCT, LTC4S | ALDH1A1 1601/4885MAPT 389/4885LMNA 99/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.